Sex

Visit (Number) vs Psychomotor Vigilance Test (PVT) Trial Length
N Mean StdDev Median Min Max Unknown Total
Baseline (BL) - - - - - - 1,516 1,516
Clinical Evaluation (CE) - - - - - - 1,516 1,516
Diagnostic Visit (DX) 1,199 600.3 ± 8.7 600.0 600.0 900.0 317 1,516
CPAP Titration Visit (CPAP) - - - - - - 1,516 1,516
Two Month Post-CPAP Neurocognitive Visit (2M) 877 600.0 ± 0.0 600.0 600.0 600.0 639 1,516
Four Month Post-CPAP Neurocognitive Visit (4M) - - - - - - 1,516 1,516
Six Month Post-CPAP Neurocognitive Visit (6M) 848 600.0 ± 0.0 600.0 600.0 600.0 668 1,516
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Baseline (BL)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Male - - - - - - 958 958
Female - - - - - - 558 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Clinical Evaluation (CE)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Male - - - - - - 958 958
Female - - - - - - 558 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Diagnostic Visit (DX)
N Mean StdDev Median Min Max Unknown Total
Total 1,199 600.3 ± 8.7 600.0 600.0 900.0 317 1,516
Male 767 600.0 ± 0.0 600.0 600.0 600.0 191 958
Female 432 600.7 ± 14.4 600.0 600.0 900.0 126 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
CPAP Titration Visit (CPAP)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Male - - - - - - 958 958
Female - - - - - - 558 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Two Month Post-CPAP Neurocognitive Visit (2M)
N Mean StdDev Median Min Max Unknown Total
Total 877 600.0 ± 0.0 600.0 600.0 600.0 639 1,516
Male 569 600.0 ± 0.0 600.0 600.0 600.0 389 958
Female 308 600.0 ± 0.0 600.0 600.0 600.0 250 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Four Month Post-CPAP Neurocognitive Visit (4M)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Male - - - - - - 958 958
Female - - - - - - 558 558
Gender vs Psychomotor Vigilance Test (PVT) Trial Length
Six Month Post-CPAP Neurocognitive Visit (6M)
N Mean StdDev Median Min Max Unknown Total
Total 848 600.0 ± 0.0 600.0 600.0 600.0 668 1,516
Male 550 600.0 ± 0.0 600.0 600.0 600.0 408 958
Female 298 600.0 ± 0.0 600.0 600.0 600.0 260 558
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Baseline (BL)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Native American - - - - - - 28 28
Asian - - - - - - 89 89
Black - - - - - - 172 172
Hispanic - - - - - - 116 116
White - - - - - - 1,102 1,102
Other - - - - - - 9 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Clinical Evaluation (CE)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Native American - - - - - - 28 28
Asian - - - - - - 89 89
Black - - - - - - 172 172
Hispanic - - - - - - 116 116
White - - - - - - 1,102 1,102
Other - - - - - - 9 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Diagnostic Visit (DX)
N Mean StdDev Median Min Max Unknown Total
Total 1,199 600.3 ± 8.7 600.0 600.0 900.0 317 1,516
Native American 20 600.0 ± 0.0 600.0 600.0 600.0 8 28
Asian 71 600.0 ± 0.0 600.0 600.0 600.0 18 89
Black 115 600.0 ± 0.0 600.0 600.0 600.0 57 172
Hispanic 83 600.0 ± 0.0 600.0 600.0 600.0 33 116
White 902 600.3 ± 10.0 600.0 600.0 900.0 200 1,102
Other 8 600.0 ± 0.0 600.0 600.0 600.0 1 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
CPAP Titration Visit (CPAP)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Native American - - - - - - 28 28
Asian - - - - - - 89 89
Black - - - - - - 172 172
Hispanic - - - - - - 116 116
White - - - - - - 1,102 1,102
Other - - - - - - 9 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Two Month Post-CPAP Neurocognitive Visit (2M)
N Mean StdDev Median Min Max Unknown Total
Total 877 600.0 ± 0.0 600.0 600.0 600.0 639 1,516
Native American 13 600.0 ± 0.0 600.0 600.0 600.0 15 28
Asian 48 600.0 ± 0.0 600.0 600.0 600.0 41 89
Black 76 600.0 ± 0.0 600.0 600.0 600.0 96 172
Hispanic 65 600.0 ± 0.0 600.0 600.0 600.0 51 116
White 672 600.0 ± 0.0 600.0 600.0 600.0 430 1,102
Other 3 600.0 ± 0.0 600.0 600.0 600.0 6 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Four Month Post-CPAP Neurocognitive Visit (4M)
N Mean StdDev Median Min Max Unknown Total
Total - - - - - - 1,516 1,516
Native American - - - - - - 28 28
Asian - - - - - - 89 89
Black - - - - - - 172 172
Hispanic - - - - - - 116 116
White - - - - - - 1,102 1,102
Other - - - - - - 9 9
Race/Ethnicity vs Psychomotor Vigilance Test (PVT) Trial Length
Six Month Post-CPAP Neurocognitive Visit (6M)
N Mean StdDev Median Min Max Unknown Total
Total 848 600.0 ± 0.0 600.0 600.0 600.0 668 1,516
Native American 13 600.0 ± 0.0 600.0 600.0 600.0 15 28
Asian 50 600.0 ± 0.0 600.0 600.0 600.0 39 89
Black 75 600.0 ± 0.0 600.0 600.0 600.0 97 172
Hispanic 61 600.0 ± 0.0 600.0 600.0 600.0 55 116
White 646 600.0 ± 0.0 600.0 600.0 600.0 456 1,102
Other 3 600.0 ± 0.0 600.0 600.0 600.0 6 9